#United States #New York #Pomerantz LLP #PepGen Inc #FDA Clinical Trial

Pomerantz Law Firm Investigates PepGen Inc.

In the latest developments for investors of PepGen Inc. (NASDAQ: PEPG), Pomerantz LLP, a renowned law firm known for its expertise in corporate and securities class litigation, is actively investigating potential claims surrounding the company. This probe primarily stems from serious allegations of securities fraud associated with the company and its executives.

On December 16, 2024, PepGen Inc. faced a significant setback when it disclosed a clinical hold notice from the U.S. Food and Drug Administration (FDA). The notification puts on hold PepGen's Investigational New Drug (IND) application, which was crucial for initiating a clinical trial named CONNECT2-EDO51, aimed at addressing Duchenne muscular dystrophy (DMD). This enforcement by the FDA has raised alarms among investors, leading to a sharp decline in PepGen's stock price, which fell by 3.63% to $4.51 per share on the same day.

The legal investigation centers around whether PepGen, along with pertinent officers and directors, may have engaged in fraudulent activities or other illegal business practices that misled investors. Shareholders impacted by these developments are being urged to contact Pomerantz LLP for potential participation in a class action lawsuit.

Founded over 85 years ago by Abraham L. Pomerantz, the firm has a long-standing reputation for fighting on behalf of victims of securities fraud and corporate misconduct. They have successfully recovered substantial damages for class members over the decades. The current investigation reiterates their commitment to ensuring accountability in corporate governance and protecting investor rights.

As regulatory scrutiny increases, investors must remain vigilant about the potential implications surrounding PepGen's situation. The law firm's history of championing for shareholder rights and its formidable expertise in securities class actions underscores the gravity of PepGen's current dilemma.

In these complex legal waters, those invested in PepGen Inc. must consider their options, particularly in light of the risks presented by the FDA's hold on the clinical trial. Given the critical nature of the anticipated clinical work related to DMD, the implications of this investigation warrant close examination and consideration by investors alike.

To stay abreast of any updates, investors are encouraged to reach out to Danielle Peyton at Pomerantz LLP via the provided contact details. The outcome of these investigations could significantly impact PepGen and its stakeholders, potentially altering the trajectory of its developmental projects and stock performance going forward. Investors are advised to monitor the situation closely and to engage with legal counsel as necessary to safeguard their interests.

For more information on this ongoing investigation, or to learn how to join the class action, interested parties may visit the official Pomerantz website or reach out directly to their offices situated in major cities globally, including New York, Chicago, London, and more.

In conclusion, as this story unfolds, it remains clear that the consequences of the FDA's recent actions, compounded by the legal scrutiny from Pomerantz LLP, could lead to weighty developments for PepGen Inc. and its investors in the near future.